Tarsus Pharmaceuticals, Inc.
TARS
Rang in aandelen
#4589
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aandeelprijs
$71.12
Marktkapitalisatie
$3.33B
Verandering (1 dag)
2.33%
Verandering (1 jaar)
-0.10%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Categorie
Healthcare
P/S-ratio voor Tarsus Pharmaceuticals, Inc. (TARS)
P/S-ratio op October 2026 TTM: 5.13
Volgens de meest recente financiële rapporten en aandelenkoers van Tarsus Pharmaceuticals, Inc. is de huidige P/S-ratio (TTM) 5.13. Eind 2023 had het bedrijf een P/S-ratio van 34.10.
P/S-ratiohistoriek voor Tarsus Pharmaceuticals, Inc. van 2018 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 5.13 | -54.93% |
| 2024 | 11.38 | -66.63% |
| 2023 | 34.10 | 143.94% |
| 2022 | 13.98 | 72.40% |
| 2021 | 8.11 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | 95.38% |
US
|
|
| 40.55 | 690.54% |
US
|
|
| 3.96 | -22.78% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 97.80% |
NL
|
